(NASDAQ: NKTX) Nkarta's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Nkarta's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast NKTX's revenue for 2028 to be $2,824,110,649, with the lowest NKTX revenue forecast at $2,824,110,649, and the highest NKTX revenue forecast at $2,824,110,649. On average, 2 Wall Street analysts forecast NKTX's revenue for 2029 to be $5,127,392,852, with the lowest NKTX revenue forecast at $2,364,305,699, and the highest NKTX revenue forecast at $7,890,480,005.
In 2030, NKTX is forecast to generate $9,254,780,896 in revenue, with the lowest revenue forecast at $1,184,991,152 and the highest revenue forecast at $14,215,636,368.